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Abstract 
Heart failure is a serious cause of morbidity and mortality worldwide. The advent 
of implantable cardiac assist devices has generated a new arsenal for treating 
severe heart failure. However, the potential ramifications of ventricular assist 
device (VAD) usage are not fully understood.  Immune modulation resulting from 
VAD implantation is an area of growing research. Although we do not fully 
understand the mechanisms contributing to host immune alteration, changes in 
cytokine concentrations, deceased lymphocyte activity, and the local effects of 
device materials have been shown to down regulate immune function. Infection is 
a serious complication that affects prognosis in this patient population. 
Malnutrition, critical status, and cardiovascular stress are additional predisposing 
factors in this fragile group. Driveline and surgery-associated infections are the 
most commonly identified culprits. However, decreased host immune function 
facilitates atypical infections including systemic fungemia and viremia. This case 
is an interesting example of a VAD associated immune system compromise. 
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Background 
Heart failure is one of the leading causes of morbidity and mortality worldwide 
and affects 1-2% of the population in developed nations.1 Because of the rising 
incidence of heart failure, transplantation has become an increasingly necessary 
mode of definitive treatment. Unfortunately, the limited availability of donor hearts 
has left many patients seeking other treatment options.1,2 Implantable devices 
have become a viable choice for patients suffering from heart failure requiring a 
bridge to transplantation or destination therapy.2 However, many of the effects of 
ventricular assist devices (VADs) on the human body are not completely 
understood. One of the unexpected consequences of VAD usage is the alteration 
of immune systems after implantation.    
Immune modulation related to cardiac pathology is a topic of ongoing research. 
Some studies have identified associations between heart failure and decreased 
immune function.3 This is believed to result from increased inhibitory chemical 
mediators and immune suppressive T cell activity3. Other cardiac conditions 
including coronary artery disease, acute heart failure, and valvular dysfunction, 
have also been connected with decreased immune function.3,4,5,6 Although the 
exact mechanism of immune modulation in each of these conditions is not 
understood, a bulk of evidence suggests that immune dysfunction contributes to 
disease processes and prolongs recovery.3,4  
The effect of implantable devices on the immune system is a thriving area of 
investigation. Studies have shown that VAD utilization in heart failure patients is 
linked to decreased immunity. Because of the acute flux of chemical messengers 
after implantation, the net change in immune mediators results in decreased 
immune activity.7 Mechanisms associated with VAD-induced immune comprise 
include increased immune inhibitory chemical mediators, decreased immune 
stimulatory messengers, reduced circulating lymphocytes, and direct interaction 
between device surfaces and host tissue.7,8  
The time frame of immune compromise in these cases is not well understood. 
Studies have suggested that there is an acute decrease in immunity soon after 
VAD placement. However, the duration of this state requires further 
investigation.9 Some research has evaluated the chemical mediators of immune 
function and found that these messengers return to baseline levels six months 
after implantation of the device.9 These data suggest that there may be adaptive 
mechanisms for stabilizing immune function that is initially compromised by the 
implantation of VADs.  
In states of immune compromise, patients are more susceptible to a myriad of 
infections. Viral and fungal infections are among the most common infectious 
etiologies seen in immune-compromised patients. Because immunecompetent 
hosts are generally able to fend off these infections, their presence has come to 
be associated with immunodeficient states. Heart failure and VAD implantation 
are not routinely recognized as states with decreased immune function. 
However, overwhelming evidence suggests that immune function is significantly 
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immunecompromise resulting in multiple infectious processes to serve as a 
reminder for the potential immune dysfunction occurring after VAD implantation.  
Case Presentation 
A 65-year-old Hispanic man presented to the emergency medical center with 
sub-sternal chest pain characterized as pressure with an intensity of nine out of 
ten. The non-radiating pain was ongoing over the past day and associated with 
diaphoresis, nausea, and vomiting. The patient’s past medical history included 
hypertension, dyslipidemia, tobacco use, and coronary artery disease that 
required percutaneous intervention with a drug-eluting stent to the left anterior 
descending artery six years prior. The patient had no history of immune 
compromise, recurring infections, HIV, or hepatitis. He had an extensive family 
history of coronary artery disease, with an uncle and two cousins who 
succumbed to myocardial infarctions before the age of fifty.  At the time of 
presentation, the alert patient was tachycardic, hypotensive, and tachypneic.  His 
physical exam was notable for lethargy, diaphoresis, crackles at lung bases, and 
tachycardia. No murmurs, extra heart sounds, jugular venous distention, or 
peripheral edema were observed. Ophthalmoscopic examination was free of 
abnormalities.  
The patient underwent laboratory and electrocardiographic evaluation, which 
revealed troponin elevation, liver transaminase increase, and an inferior ST 
segment elevation myocardial infarction. Transaminase elevation was credited to 
hepatic congestion occurring secondary to a cardiac event. At this time an 
elevated white blood cell count of 19000 per microliter was noted. There was no 
history of infection, immunodeficiency, likely sources of infection, or fever. The 
leukocytosis was attributed to a systemic inflammatory reaction syndrome and 
the patient was started on broad-spectrum antibiotics. He was urgently taken to 
the cardiac catheterization laboratory, where a complete occlusion of the right 
coronary artery (RCA) was identified. This discovery prompted deployment of a 
drug-eluting stent in the RCA. Although the patient tolerated the procedure well, 
over the course of the night, the patient complained of increasing chest pain and 
shortness of breath.  A chest radiograph showed pulmonary edema. Diuresis 
with intravenous Lasix was initiated, but the patient’s shortness of breath 
worsened with increasing need for oxygen supplementation.  Because of his 
worsening condition, a trans-thoracic echocardiogram was performed. A new 
one-centimeter ventricular septal defect (VSD) along with a depressed ejection 
fraction of 45% was discovered. The patient’s need for further cardiac support 
prompted intraaortic balloon pump placement and transfer to the Center for 
Advanced Heart Failure for evaluation for ventricular assist device implantation.  
Upon arrival to our center, the patient was intubated and underwent 
TandemHeart (CardiacAssist, Inc.) peripheral ventricular assist device (pVAD) 
placement due to cardiogenic shock and an ischemic VSD. The patient continued 
diuresis while concurrently being weaned from vasopressor support for refractory 
cardiogenic shock. Leukocytosis improved with left ventricular support and the 
patient remained afebrile. Multiple blood, urine, and sputum cultures were 
performed with no growth.  He was continued on broad-spectrum antibiotics due 
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stabilization of the septal defect diameter and myocardial scarring that would 
facilitate closure device success.10,12  
Two days after pVAD placement, the patient manifested his first fever of 101º F. 
New sputum, blood, and urine cultures were obtained and found to be negative. 
Procalcitonin levels were within normal range. Abdominal ultrasound was 
performed and showed no acute abnormalities or signs of infection.  Seven days 
after TandemHeart placement, the patient’s condition acutely worsened. 
Hypotension requiring vasopressors, increased ventilator dependence, 
worsening leukocytosis, and bilateral lung opacities observed on chest 
radiographs raised concern for acute respiratory distress syndrome. The 
antibiotic regimen was escalated to include meropenem, vancomycin, and 
micafungin.  Bronchoscopy with bronchoalveolar lavage (BAL) was performed. 
Diffuse alveolar hemorrhage was diagnosed by obtaining progressively blood-
tinged fluid in the lavage samples. The BAL fluid was cultured and found to 
contain yeast.  Additionally, microthrombi were seen in the patient’s toes along 
with falling platelet counts. This prompted concern for heparin-induced 
thrombocytopenia, which was confirmed by the presence of heparin-associated 
antibodies. Although bivalirudin was substituted for heparin, platelet depletion 
and clot formation persisted, and required therapy with plasmaphoresis. Pro-
thrombotic activity was responsible for clot formation in the TandemHeart, which 
was exchanged for a CentriMag (Thoratec Corporation) blood pump for left 
ventricular support 10 days after TandemHeart placement.  The patient was also 
noted to have elevated lipase levels that peaked 2,737 units per liter. Evaluation 
with computed tomography scans revealed hemorrhagic pancreatitis. Surgical 
and gastroenterology consultants deemed surgical intervention unnecessary.  
Eleven days after the patient’s myocardial infarction, percutaneous VSD repair 
was attempted three times without success. Because of severe biventricular 
failure and continued deterioration, the decision was made to implant a 
SynCardia Total Artificial Heart (TAH) (SynCardia Systems, Inc) as a bridge to 
definitive therapy. The operation was performed 19 days after the initial cardiac 
event. The patient had an arduous postoperative course complicated by 
prolonged intubation requiring tracheostomy, renal failure requiring hemodialysis, 
and persistent leukocytosis. Multiple bronchoscopies and BALs were performed 
with cultures repeatedly growing yeast.  Speciation of the yeast noted in the BAL 
fluid was unsuccessful. The patient was treated with escalating regimens of 
antifungal therapy including fluconazole, micafungin, and amphotericin B. 
Concurrently, braod-spectrum antibacterial therapy with intravenous vancomycin 
and cefepime that was escalated to meropenem. Despite aggressive 
antimicrobial therapy, leukocytosis persisted in the face of clinical deterioration.  
Procalcitonin remained at normal values.  
Forty-eight days after presentation, fungal blood cultures from the arterial and 
central venous catheters grew Candida galbarata. Seven days later, the patient 
complained of vision disturbances. Bilateral dilated eye exams performed by 
ophthalmologists revealed peripapillary vessels obscured by infiltrates and 
intraretinal hemorrhages consistent with cytomegalovirus (CMV). Polymerase 
chain reaction analysis revealed a viral load of 3,606 copies per milliliter, which 
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were atypical infections in immunocompetent hosts. The presence of these 
infections supported an induced immunocompromised state. Reevaluation of HIV 
and hepatitis statuses found both to be negative. Despite aggressive treatment, 
the patient continued to deteriorate over several weeks and developed worsening 
hepatic failure, renal failure, ventilator dependence, and gastrointestinal bleeds. 
After discussion with the family, the patient was transitioned to palliative care and 
expired 88 days after admission.  
Discussion  
Artificial device implantation has unintended consequences on host immune 
systems. Processes that contribute to VAD-associated immune modulation were 
described by Itescu and colleagues to include protein absorption from device 
surfaces, material composition changes after implantation, mechanical stress on 
circulatory components, and effects of the material on host tissues.7 That group 
also noted systemic and local T cell activation in response to VADs. The 
activated CD4 and CD8 T cells displayed increased CD95 expression, which is 
associated with T cell-mediated apoptotic pathways. The increased apoptosis 
was experimentally observed by noting elevated binding of annexin V to 
phosphatidylserine located on T cell membranes. Phosphatidylserine is an 
apoptosis-associated cell surface component for which annexin V has high 
affinity.  Qualitative analysis of the chemical interaction between annexin V and 
phosphatidylserine serves as a marker for evaluating apoptotic activity. 
Additionally, Itescu’s group reported B cell hyperactivity and increased major 
histocompatibility complex-targeted antibody production in VAD patients.7 
Overall, lymphocytic lineages including B cells, helper T cells, and cytotoxic T 
cells display altered function in this population. 
Itescheu and colleagues correlated VAD related immune suppression with 
increased predisposition for Candida infections including albicans, parapsilosis, 
and galbrata sepsis. In their prevalence study evaluating 78 patients, 28% 
developed disseminated Candida infections compared to only 3% in a matched 
population without left VADs (LVADs). Also, cases of CMV viremia following  
LVAD implantation have been reported.8,9   
Other studies have also shown increased B and T cell apoptosis in LVAD 
patients.8 Increased immune suppressive cytokine expression concurrent with 
down regulation of pro-inflammatory cytokines such as IL-2 and TNF-a has also 
been observed with concurrent increase in the immune suppressive cytokine IL-
10.10 Mitchell and colleagues contributed valuable information regarding the time 
frames of this immune modulation. Their work noted that decreased pathways of 
cellular immunity, pro-inflammatory cytokine synthesis, shifts in apoptotic 
pathways, and downregulation of immune proliferation were observed within 7 
days after LVAD implantation.   Other studies have noted decreased expression 
in genes related to immune activity as early as 1 day after implantation.11  
Our patient received therapy with the TandemHeart pVAD temporarily and then 
underwent implantation of a TAH. He manifested fungal growth in blood cultures 
identified as systemic Candida galbarata 75 days after LVAD and 59 days after 
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days after the Candida was isolated. The presence of these microorganisms is 
highly suggestive of decreased immunity. Prior to his cardiovascular event, the 
patient was immunecompetent with no previous history of similar infections. Over 
the course of his treatment with these devices, his immune functions gradually 
deteriorated. While the waning of his immune function may be multifactorial, 
device implantation was a contributing component of his decline.  
Although LVADs have been associated with decreased immunity, the effect of 
TAH placement on the immune system has not been well investigated. The 
fundamental mechanisms of immune dysfunction proposed by Itescheu and 
colleagues remain true in the presence of a TAH. Further investigations into the 
mechanisms of immune modulation concerning these devices are necessary. 
Our case serves as an example of immune comprise related to LVAD and TAH 
utilization. Although other etiologies may have contributed to the patient’s 
decline, the waning of his immune function was a major source of his clinical 
deterioration and eventual demise. We hope this case serves as a reminder of 
artificial device-associated immune alterations and prompts early consideration 
of infectious etiologies related to immunocompromised states. Increased 
awareness of this phenomenon may serve to facilitate early identification of 
causative organisms and expedite targeted intervention.  
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